An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Inclusion Criteria:
- Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015.
Exclusion Criteria:
Clinical.Trials@bms.com855-907-3286
Florida, Vicente López, Buenos Aires 1602, Argentina
CABA, Distrito Federal C1425FVH, Argentina
CABA, 4190, Argentina
Shenzhen Shi, Guangdong 518020, China
Yichang Shi, HE 443099, China
Shandong, Shandong 250012, China
Shanghai Shi, 200030, China
Ahemdabad, 380060, India
Seto-shi, Aichi-ken 489-8642, Japan
Kamogawa-Shi, Chiba 296-0041, Japan
Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
Iizuka-shi, Fukuoka 820-8505, Japan
Kurume-Shi, Fukuoka 830-0011, Japan
Himeji-Shi, Hyōgo 670-8520, Japan
Naka-gun, Ibaraki 3191113, Japan
Matsusaka-shi, Mie-ken 515-8544, Japan
Tenri-shi, Nara 632-8552, Japan
Ginowan-Shi, Okinawa 901-2214, Japan
Izumo-shi, Shimane 693-8501, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Bunkyo-ku, Tokyo 113-8519, Japan
Bunkyo-Ku, Tokyo 113-8603, Japan
Minato-ku, Tokyo 105-8471, Japan
Mitaka-shi, Tokyo 181-8611, Japan
Shinjyu-Ku, Tokyo 162-8655, Japan
Shinjyuku-ku, 160-0023, Japan
Col Garcia Binersa, Yucatán 97070, Mexico
Namdong-gu, Incheon-gwangyeoksi [Incheon] 21565, South Korea
Kyunggi-do, 463-707, South Korea